Fibroblast activation protein (FAP) as a novel metabolic target

Molecular Metabolism

Volumn 5, Issue 10, 2016, Pages 1015-1024

  Sánchez Garrido, Miguel Angel ^a,b,c   Habegger, Kirk M ^d   Clemmensen, Christoffer ^a,b,c   Holleman, Cassie ^d   Müller, Timo D ^a,b,c   Perez Tilve, Diego ^e   Li, Pengyun ^g   Agrawal, Archita S ^g   Finan, Brian ^a,b,c   Drucker, Daniel J ^f   Tschöp, Matthias H ^a,b,c   DiMarchi, Richard D ^g   Kharitonenkov, Alexei ^g  

^a Helmholtz Research Center   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f MOUNT SINAI HOSPITAL   (Canada)

^g INDIANA UNIVERSITY   (United States)

Author keywords

Diabetes; DPP4; FAP; FGF21; Metabolic regulation; Obesity

Indexed keywords

CHOLESTEROL; FIBROBLAST ACTIVATION PROTEIN; FIBROBLAST GROWTH FACTOR 21; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; SERINE PROTEINASE; TALABOSTAT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET INDUCED OBESITY; DOSE TIME EFFECT RELATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENERGY EXPENDITURE; ENZYMATIC DEGRADATION; ENZYME INHIBITION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; IN VITRO STUDY; INSULIN SENSITIVITY; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; KNOCKOUT MOUSE; MALE; METABOLIC CLEARANCE; METABOLIC REGULATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; TIME SERIES ANALYSIS; WEIGHT REDUCTION;

EID: 84979642701     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.07.003     Document Type: Article

References (47)

1. [1] Rettig, W.J., Chesa, P.G., Beresford, H.R., Feickert, H.J., Jennings, M.T., Cohen, J., et al. Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. Cancer Research 46 (1986), 6406–6412.
2. [2] Rettig, W.J., Su, S.L., Fortunato, S.R., Scanlan, M.J., Raj, B.K., Garin-Chesa, P., et al. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. International Journal of Cancer Journal International du Cancer 58 (1994), 385–392.
3. [3] Keane, F.M., Yao, T.W., Seelk, S., Gall, M.G., Chowdhury, S., Poplawski, S.E., et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio 4 (2013), 43–54.
4. [4] Lee, K.N., Jackson, K.W., Christiansen, V.J., Lee, C.S., Chun, J.G., McKee, P.A., Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 107 (2006), 1397–1404.
5. [5] Liu, R., Li, H., Liu, L., Yu, J., Ren, X., Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biology & Therapy 13 (2012), 123–129.
6. [6] Keane, F.M., Nadvi, N.A., Yao, T.W., Gorrell, M.D., Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. The FEBS Journal 278 (2011), 1316–1332.
7. [7] Garin-Chesa, P., Old, L.J., Rettig, W.J., Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proceedings of the National Academy of Sciences of the United States of America 87 (1990), 7235–7239.
8. [8] Brennen, W.N., Isaacs, J.T., Denmeade, S.R., Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Molecular Cancer Therapeutics 11 (2012), 257–266.
9. [9] Cheng, J.D., Valianou, M., Canutescu, A.A., Jaffe, E.K., Lee, H.O., Wang, H., et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Molecular Cancer Therapeutics 4 (2005), 351–360.
10. [10] Adams, S., Miller, G.T., Jesson, M.I., Watanabe, T., Jones, B., Wallner, B.P., PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Research 64 (2004), 5471–5480.
11. [11] Narra, K., Mullins, S.R., Lee, H.O., Strzemkowski-Brun, B., Magalong, K., Christiansen, V.J., et al. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biology & Therapy 6 (2007), 1691–1699.
12. [12] Hamson, E.J., Keane, F.M., Tholen, S., Schilling, O., Gorrell, M.D., Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clinical Applications 8 (2014), 454–463.
13. [13] Mulvihill, E.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocrine Reviews 35 (2014), 992–1019.
14. [14] Wong, P.F., Gall, M.G., Bachovchin, W.W., McCaughan, G.W., Keane, F.M., Gorrell, M.D., Neuropeptide Y is a physiological substrate of fibroblast activation protein: enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma. Peptides 75 (2016), 80–95.
15. [15] Kharitonenkov, A., Adams, A.C., Inventing new medicines: the FGF21 story. Molecular Metabolism 3 (2014), 221–229.
16. [16] Dunshee, D.R., Bainbridge, T.W., Kljavin, N.M., Zavala-Solorio, J., Schroeder, A.C., Chan, R., et al. Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21. The Journal of Biological Chemistry, 2016.
17. [17] Zhen, E.Y., Jin, Z., Ackermann, B.L., Thomas, M.K., Gutierrez, J.A., Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. The Biochemical Journal, 2015.
18. [18] Coppage, A.L., Heard, K.R., DiMare, M.T., Liu, Y., Wu, W., Lai, J.H., et al. Human FGF-21 is a substrate of fibroblast activation protein. PLoS One, 11, 2016, e0151269.
19. [19] Niedermeyer, J., Kriz, M., Hilberg, F., Garin-Chesa, P., Bamberger, U., Lenter, M.C., et al. Targeted disruption of mouse fibroblast activation protein. Molecular and Cellular Biology 20 (2000), 1089–1094.
20. [20] Gorrell M, Song S, Wang X. Novel metabolic disease therapy. US20120053222; 2012.
21. [21] Ryabtsova, O., Jansen, K., Van Goethem, S., Joossens, J., Cheng, J.D., Lambeir, A.M., et al. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. Bioorganic & Medicinal Chemistry Letters 22 (2012), 3412–3417.
22. [22] Chen, S.J., Jiaang, W.T., Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein. Current Topics in Medicinal Chemistry 11 (2011), 1447–1463.
23. [23] Tschop, M.H., Speakman, J.R., Arch, J.R., Auwerx, J., Bruning, J.C., Chan, L., et al. A guide to analysis of mouse energy metabolism. Nature Methods 9 (2012), 57–63.
24. [24] Coskun, T., Bina, H.A., Schneider, M.A., Dunbar, J.D., Hu, C.C., Chen, Y., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149 (2008), 6018–6027.
25. [25] Xu, J., Lloyd, D.J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58 (2009), 250–259.
26. [26] Badman, M.K., Koester, A., Flier, J.S., Kharitonenkov, A., Maratos-Flier, E., Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150 (2009), 4931–4940.
27. [27] Assini, J.M., Mulvihill, E.E., Burke, A.C., Sutherland, B.G., Telford, D.E., Chhoker, S.S., et al. Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21. Endocrinology 156 (2015), 2087–2102.
28. [28] Gaich, G., Chien, J.Y., Fu, H., Glass, L.C., Deeg, M.A., Holland, W.L., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metabolism 18 (2013), 333–340.
29. [29] Dong, J.Q., Rossulek, M., Somayaji, V.R., Baltrukonis, D., Liang, Y., Hudson, K., et al. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. British Journal of Clinical Pharmacology, 2015.
30. [30] Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and Type 2 diabetic subjects. Cell Metabolism 23 (2016), 427–440.
31. [31] Hager, T., Spahr, C., Xu, J., Salimi-Moosavi, H., Hall, M., Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Analytical Chemistry 85 (2013), 2731–2738.
32. [32] Micanovic, R., Raches, D.W., Dunbar, J.D., Driver, D.A., Bina, H.A., Dickinson, C.D., et al. Different roles of N- and C- termini in the functional activity of FGF21. Journal of Cellular Physiology 219 (2009), 227–234.
33. [33] Yie, J., Hecht, R., Patel, J., Stevens, J., Wang, W., Hawkins, N., et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Letters 583 (2009), 19–24.
34. [34] Hecht, R., Li, Y.S., Sun, J., Belouski, E., Hall, M., Hager, T., et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS One, 7, 2012, e49345.
35. [35] Weng, Y., Chabot, J.R., Bernardo, B., Yan, Q., Zhu, Y., Brenner, M.B., et al. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice. PLoS One, 10, 2015, e0119104.
36. [36] Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., et al. FGF-21 as a novel metabolic regulator. The Journal of Clinical Investigation 115 (2005), 1627–1635.
37. [37] Kharitonenkov, A., Beals, J.M., Micanovic, R., Strifler, B.A., Rathnachalam, R., Wroblewski, V.J., et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One, 8, 2013, e58575.
38. [38] Xu, J., Wei, L., Mathvink, R., Edmondson, S.D., Mastracchio, A., Eiermann, G.J., et al. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors. Bioorganic & Medicinal Chemistry Letters 16 (2006), 1346–1349.
39. [39] Mu, J., Woods, J., Zhou, Y.P., Roy, R.S., Li, Z., Zycband, E., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006), 1695–1704.
40. [40] Cunningham, C.C., Talabostat. Expert Opinion on Investigational Drugs 16 (2007), 1459–1465.
41. [41] Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y.Y., Hager, T., Patel, J., et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects. American Journal of Physiology Endocrinology and Metabolism 297 (2009), E1105–E1114.
42. [42] Fisher, F.M., Chui, P.C., Antonellis, P.J., Bina, H.A., Kharitonenkov, A., Flier, J.S., et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59 (2010), 2781–2789.
43. [43] Adams, A.C., Kharitonenkov, A., FGF21: the center of a transcriptional nexus in metabolic regulation. Current Diabetes Reviews 8 (2012), 285–293.
44. [44] Habegger, K.M., Stemmer, K., Cheng, C., Muller, T.D., Heppner, K.M., Ottaway, N., et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62 (2013), 1453–1463.
45. [45] Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabolism 5 (2007), 415–425.
46. [46] Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., Maratos-Flier, E., Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 5 (2007), 426–437.
47. [47] Lundasen, T., Hunt, M.C., Nilsson, L.M., Sanyal, S., Angelin, B., Alexson, S.E., et al. PPARalpha is a key regulator of hepatic FGF21. Biochemical and Biophysical Research Communications 360 (2007), 437–440.